This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Tubulin	<p><i>In vitro</i> and mouse studies have identified aryloxazole-based tubulin inhibitors that could help treat cancer. Screening of a small molecule library and <i>in vitro</i> testing of aryloxazole analogs identified several lead compounds that inhibited tubulin polymerization and reduced the viability of human leukemia, lung cancer and colorectal cancer cell lines at nanomolar IC₅₀ values. In mice bearing xenograft colorectal tumors, one lead compound decreased tumor growth compared with no treatment. Future studies could include optimizing and testing the lead compounds in other tumor models.</p> <p>SciBX 6(46); doi:10.1038/scibx.2013.1315 Published online Dec. 5, 2013</p>	Patent and licensing status unavailable	<p>Choi, M.J. <i>et al.</i> <i>J. Med. Chem.</i>; published online Oct. 27, 2013; doi:10.1021/jm400840p Contact: GhilSoo Nam, Korea Institute of Science and Technology, Seoul, South Korea e-mail: gsnam@kist.re.kr Contact: Ae Nim Pae, same affiliation as above e-mail: anpae@kist.re.kr</p>